Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 463

1.

H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components.

Andreiuolo F, Lisner T, Zlocha J, Kramm C, Koch A, Bison B, Gareton A, Zanello M, Waha A, Varlet P, Pietsch T.

Acta Neuropathol Commun. 2019 May 20;7(1):78. doi: 10.1186/s40478-019-0731-5.

2.

SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma.

Gnekow AK, Kandels D, van Tilburg C, Azizi AA, Opocher E, Stokland T, Driever PH, Meeteren AYNSV, Thomale UW, Schuhmann MU, Czech T, Goodden JR, Warmuth-Metz M, Bison B, Avula S, Kortmann RD, Timmermann B, Pietsch T, Witt O.

Klin Padiatr. 2019 May;231(3):107-135. doi: 10.1055/a-0889-8256. Epub 2019 May 20.

PMID:
31108561
3.

Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.

Pfaff E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, Worst BC, Stark S, Witt H, Pajtler KW, van Tilburg CM, Witt R, Milde T, Jakobs M, Fiesel P, Frühwald MC, Hernáiz Driever P, Thomale UW, Schuhmann MU, Metzler M, Bochennek K, Simon T, Dürken M, Karremann M, Knirsch S, Ebinger M, von Bueren AO, Pietsch T, Herold-Mende C, Reuss DE, Kiening K, Lichter P, Eggert A, Kramm CM, Pfister SM, Jones DTW, Bächli H, Witt O.

Eur J Cancer. 2019 Jun;114:27-35. doi: 10.1016/j.ejca.2019.03.019. Epub 2019 Apr 22.

PMID:
31022591
4.

Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1.

Thomas C, Knerlich-Lukoschus F, Reinhard H, Johann PD, Sturm D, Sahm F, Bens S, Vogt J, Nemes K, Oyen F, Kordes U, Siebert R, Schneppenheim R, Messing-Jünger M, Pietsch T, von Deimling A, Paulus W, Pfister SM, Kool M, Frühwald MC, Hasselblatt M.

Acta Neuropathol. 2019 May;137(5):847-850. doi: 10.1007/s00401-019-02001-3. Epub 2019 Apr 3. No abstract available.

PMID:
30945057
5.

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.

Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M.

J Transl Med. 2019 Mar 20;17(1):96. doi: 10.1186/s12967-019-1846-y.

6.

Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.

Benesch M, Mynarek M, Witt H, Warmuth-Metz M, Pietsch T, Bison B, Pfister SM, Pajtler KW, Kool M, Schüller U, Pietschmann K, Juhnke BO, Tippelt S, Fleischhack G, Schmid I, Kramm CM, Vorwerk P, Beilken A, Classen CF, Hernáiz Driever P, Kropshofer G, Imschweiler T, Lemmer A, Kortmann RD, Rutkowski S, von Hoff K.

Oncologist. 2019 Mar 8. pii: theoncologist.2018-0489. doi: 10.1634/theoncologist.2018-0489. [Epub ahead of print]

PMID:
30850560
7.

Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.

Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR.

J Neurooncol. 2019 May;142(3):435-444. doi: 10.1007/s11060-019-03127-w. Epub 2019 Mar 4.

PMID:
30830680
8.

[Neuropathology of medulloblastomas and other CNS embryonal tumors : Precision diagnostics through the integration of genetic markers].

Pietsch T.

Pathologe. 2019 Mar;40(2):140-147. doi: 10.1007/s00292-019-0580-9. Review. German.

PMID:
30790012
9.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
10.

Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA.

Hou Y, Pinheiro J, Sahm F, Reuss DE, Schrimpf D, Stichel D, Casalini B, Koelsche C, Sievers P, Wefers AK, Reinhardt A, Ebrahimi A, Fernández-Klett F, Pusch S, Meier J, Schweizer L, Paulus W, Prinz M, Hartmann C, Plate KH, Reifenberger G, Pietsch T, Varlet P, Pagès M, Schüller U, Scheie D, de Stricker K, Frank S, Hench J, Pollo B, Brandner S, Unterberg A, Pfister SM, Jones DTW, Korshunov A, Wick W, Capper D, Blümcke I, von Deimling A, Bertero L.

Acta Neuropathol. 2019 May;137(5):837-846. doi: 10.1007/s00401-019-01969-2. Epub 2019 Feb 13.

PMID:
30759284
11.

Occurrence of high-grade glioma in Noonan syndrome: Report of two cases.

El-Ayadi M, Ansari M, Kühnöl CD, Bendel A, Sturm D, Pietsch T, Kramm CM, von Bueren AO.

Pediatr Blood Cancer. 2019 May;66(5):e27625. doi: 10.1002/pbc.27625. Epub 2019 Jan 28.

PMID:
30693642
12.

Mutated SON putatively causes a cancer syndrome comprising high-risk medulloblastoma combined with café-au-lait spots.

Chiu C, Loth S, Kuhlen M, Ginzel S, Schaper J, Rosenbaum T, Pietsch T, Borkhardt A, Hoell JI.

Fam Cancer. 2019 Jul;18(3):353-358. doi: 10.1007/s10689-019-00121-z.

PMID:
30680470
13.

Case of the month 1-2019: CNS high-grade neuroepithelial tumor with BCOR alteration.

Haberler C, Reiniger L, Rajnai H, Kalev O, Gelpi E, Tamesberger M, Pietsch T.

Clin Neuropathol. 2019 Jan/Feb;38(1):4-7. doi: 10.5414/NP301162. No abstract available.

14.

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.

Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC.

Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1.

15.

Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.

Pagès M, Pajtler KW, Puget S, Castel D, Boddaert N, Tauziède-Espariat A, Picot S, Debily MA, Kool M, Capper D, Sainte-Rose C, Chrétien F, Pfister SM, Pietsch T, Grill J, Varlet P, Andreiuolo F.

Brain Pathol. 2019 May;29(3):325-335. doi: 10.1111/bpa.12664. Epub 2018 Nov 28.

PMID:
30325077
16.

Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region.

Belting M, Bång-Rudenstam A, Englund E, Pietsch T.

Neuro Oncol. 2019 Jan 1;21(1):137-138. doi: 10.1093/neuonc/noy153. No abstract available.

17.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH.

BMC Cancer. 2018 Sep 29;18(1):936. doi: 10.1186/s12885-018-4841-4.

18.

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.

Andreiuolo F, Varlet P, Tauziède-Espariat A, Jünger ST, Dörner E, Dreschmann V, Kuchelmeister K, Waha A, Haberler C, Slavc I, Corbacioglu S, Riemenschneider MJ, Leipold A, Rüdiger T, Körholz D, Acker T, Russo A, Faber J, Sommer C, Armbrust S, Rose M, Erdlenbruch B, Hans VH, Bernbeck B, Schneider D, Lorenzen J, Ebinger M, Handgretinger R, Neumann M, van Buiren M, Prinz M, Roganovic J, Jakovcevic A, Park SH, Grill J, Puget S, Messing-Jünger M, Reinhard H, Bergmann M, Hattingen E, Pietsch T.

Brain Pathol. 2019 Mar;29(2):205-216. doi: 10.1111/bpa.12659. Epub 2018 Nov 11.

PMID:
30246434
19.

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.

Ronellenfitsch MW, Zeiner PS, Mittelbronn M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M, Harter PN.

Acta Neuropathol Commun. 2018 Aug 21;6(1):81. doi: 10.1186/s40478-018-0583-4.

20.

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.

Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray MJ, Schönberger S, Czech T, Schouten-van Meeteren AYN, Kordes U, Kramm CM, van Vuurden DG, Hulleman E, Janssens GO, Solanki GA, van Veelen MC, Thomale U, Schuhmann MU, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford SC, Pfister SM, Van Gool SW.

Lancet Oncol. 2018 Aug;19(8):e419-e428. doi: 10.1016/S1470-2045(18)30364-4. Review.

PMID:
30102236
21.

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Witt H, Gramatzki D, Hentschel B, Pajtler KW, Felsberg J, Schackert G, Löffler M, Capper D, Sahm F, Sill M, von Deimling A, Kool M, Herrlinger U, Westphal M, Pietsch T, Reifenberger G, Pfister SM, Tonn JC, Weller M; German Glioma Network.

Neuro Oncol. 2018 Nov 12;20(12):1616-1624. doi: 10.1093/neuonc/noy118.

PMID:
30053291
22.

Integrative Review for Patients With Bilateral Total Knee Replacement: A Call for Nursing Practice Guidelines.

Pietsch T, David J, Vergara F.

Orthop Nurs. 2018 Jul/Aug;37(4):237-243. doi: 10.1097/NOR.0000000000000465. Review.

PMID:
30028426
23.

MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.

Nowak J, Jünger ST, Huflage H, Seidel C, Hohm A, Vandergrift LA, von Hoff K, Rutkowski S, Pietsch T, Warmuth-Metz M.

Clin Neuroradiol. 2018 Jul 19. doi: 10.1007/s00062-018-0704-2. [Epub ahead of print]

PMID:
30027327
24.

Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series.

Bächli H, Ecker J, van Tilburg C, Sturm D, Selt F, Sahm F, Koelsche C, Grund K, Sutter C, Pietsch T, Witt H, Herold-Mende C, von Deimling A, Jones D, Pfister S, Witt O, Milde T.

Klin Padiatr. 2018 Oct;230(6):305-313. doi: 10.1055/a-0637-9653. Epub 2018 Jul 11.

PMID:
29996150
25.

Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.

El-Ayadi M, Egervari K, Merkler D, McKee TA, Gumy-Pause F, Stichel D, Capper D, Pietsch T, Ansari M, von Bueren AO.

Front Neurol. 2018 Jun 19;9:398. doi: 10.3389/fneur.2018.00398. eCollection 2018.

26.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.

Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D.

Clin Cancer Res. 2018 Sep 15;24(18):4494-4504. doi: 10.1158/1078-0432.CCR-18-0763. Epub 2018 Jun 11.

PMID:
29891723
27.

Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004.

Kaufmann A, Gerber NU, Kandels D, Azizi AA, Schmidt R, Warmuth-Metz M, Pietsch T, Kortmann RD, Gnekow AK, Grotzer MA.

Neuropediatrics. 2018 Oct;49(5):314-323. doi: 10.1055/s-0038-1660503. Epub 2018 Jun 11.

PMID:
29890518
28.

Insights into the history and timing of post-European land use disturbance on sedimentation rates in catchments draining to the Great Barrier Reef.

Bartley R, Thompson C, Croke J, Pietsch T, Baker B, Hughes K, Kinsey-Henderson A.

Mar Pollut Bull. 2018 Jun;131(Pt A):530-546. doi: 10.1016/j.marpolbul.2018.04.070. Epub 2018 May 1.

PMID:
29886980
29.

Early Wound Site Seeding in a Patient with Central Nervous System High-Grade Neuroepithelial Tumor with BCOR Alteration.

Kirkman MA, Pickles JC, Fairchild AR, Avery A, Pietsch T, Jacques TS, Aquilina K.

World Neurosurg. 2018 Aug;116:279-284. doi: 10.1016/j.wneu.2018.05.158. Epub 2018 May 30.

PMID:
29859355
30.

Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.

Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU, Monoranu CM, Milde T, Wittmann A, Hartmann C, Sommer C, Paulus W, Gärtner J, Brück W, Rüdiger T, Leipold A, Jaunmuktane Z, Brandner S, Giangaspero F, Nozza P, Mora J, Morales la Madrid A, Cruz Martinez O, Hansford JR, Pietsch T, Tietze A, Hernáiz-Driever P, Stoler I, Capper D, Korshunov A, Ellison DW, von Deimling A, Pfister SM, Sahm F, Jones DTW.

Acta Neuropathol. 2018 Aug;136(2):239-253. doi: 10.1007/s00401-018-1865-4. Epub 2018 May 15.

PMID:
29766299
31.

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garrè ML, Smith H, Capper D, Pfister SM, Würdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C.

Cancer Cell. 2018 May 14;33(5):829-842.e5. doi: 10.1016/j.ccell.2018.04.004.

32.

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.

Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Baugh J, Chaney B, Hoffmann M, Lane A, Fuller C, Miles L, Hawkins C, Bartels U, Bouffet E, Goldman S, Leary S, Foreman NK, Packer R, Warren KE, Broniscer A, Kieran MW, Minturn J, Comito M, Broxson E, Shih CS, Khatua S, Chintagumpala M, Carret AS, Escorza NY, Hassall T, Ziegler DS, Gottardo N, Dholaria H, Doughman R, Benesch M, Drissi R, Nazarian J, Jabado N, Boddaert N, Varlet P, Giraud G, Castel D, Puget S, Jones C, Hulleman E, Modena P, Giagnacovo M, Antonelli M, Pietsch T, Gielen GH, Jones DTW, Sturm D, Pfister SM, Gerber NU, Grotzer MA, Pfaff E, von Bueren AO, Hargrave D, Solanki GA, Jadrijevic Cvrlje F, Kaspers GJL, Vandertop WP, Grill J, Bailey S, Biassoni V, Massimino M, Calmon R, Sanchez E, Bison B, Warmuth-Metz M, Leach J, Jones B, van Vuurden DG, Kramm CM, Fouladi M.

J Clin Oncol. 2018 Jul 1;36(19):1963-1972. doi: 10.1200/JCO.2017.75.9308. Epub 2018 May 10.

33.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

34.

The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.

Ehrhardt M, Craveiro RB, Velz J, Olschewski M, Casati A, Schönberger S, Pietsch T, Dilloo D.

J Cell Mol Med. 2018 Apr;22(4):2153-2161. doi: 10.1111/jcmm.13489. Epub 2018 Jan 29.

35.

Corrigendum to "A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report" [Eur J of Canc (2017) 206-225].

Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; Low Grade Glioma Consortium and the participating centers.

Eur J Cancer. 2018 Feb;90:156-157. doi: 10.1016/j.ejca.2017.11.017. Epub 2017 Dec 14. No abstract available.

PMID:
29248309
36.

Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms.

Zapka P, Dörner E, Dreschmann V, Sakamato N, Kristiansen G, Calaminus G, Vokuhl C, Leuschner I, Pietsch T.

J Neuropathol Exp Neurol. 2018 Feb 1;77(2):119-127. doi: 10.1093/jnen/nlx106.

PMID:
29237087
37.

Comparison of cryogenic low-pass filters.

Thalmann M, Pernau HF, Strunk C, Scheer E, Pietsch T.

Rev Sci Instrum. 2017 Nov;88(11):114703. doi: 10.1063/1.4995076.

PMID:
29195349
38.

Group 3 medulloblastoma in a patient with a GYS2 germline mutation and glycogen storage disease 0a.

Holsten T, Tsiakas K, Kordes U, Bison B, Pietsch T, Rutkowski S, Santer R, Schüller U.

Childs Nerv Syst. 2018 Mar;34(3):581-584. doi: 10.1007/s00381-017-3666-9. Epub 2017 Nov 22.

PMID:
29167993
39.

Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial.

Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, Göbel U, Alapetite C, Murray MJ, Nicholson JC.

Neuro Oncol. 2017 Nov 29;19(12):1661-1672. doi: 10.1093/neuonc/nox122.

40.

Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures.

Schwalbe EC, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Silmon A, Curtis A, Lindsey JC, Crosier S, Smith AJ, Goschzik T, Doz F, Rutkowski S, Lannering B, Pietsch T, Bailey S, Williamson D, Clifford SC.

Sci Rep. 2017 Oct 18;7(1):13421. doi: 10.1038/s41598-017-13644-1.

41.

Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis.

Beyer U, Brand F, Martens H, Weder J, Christians A, Elyan N, Hentschel B, Westphal M, Schackert G, Pietsch T, Hong B, Krauss JK, Samii A, Raab P, Das A, Dumitru CA, Sandalcioglu IE, Hakenberg OW, Erbersdobler A, Lehmann U, Reifenberger G, Weller M, Reijns MAM, Preller M, Wiese B, Hartmann C, Weber RG.

Acta Neuropathol. 2017 Dec;134(6):905-922. doi: 10.1007/s00401-017-1774-y. Epub 2017 Oct 13.

42.

Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.

Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH, Warmuth-Metz M, Bison B, Kortmann RD, Kramm CM.

Strahlenther Onkol. 2018 Mar;194(3):215-224. doi: 10.1007/s00066-017-1218-6. Epub 2017 Oct 11.

PMID:
29022050
43.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

44.

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155. Erratum in: Neuro Oncol. 2018 Feb 19;20(3):434.

45.

CNS embryonal tumours: WHO 2016 and beyond.

Pickles JC, Hawkins C, Pietsch T, Jacques TS.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):151-162. doi: 10.1111/nan.12443. Review.

PMID:
28949028
46.

Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors.

Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, Schackert G, Tonn JC, Pietsch T, von Deimling A, Loeffler M, Reifenberger G, Weller M; German Glioma Network.

Clin Cancer Res. 2017 Nov 15;23(22):6846-6855. doi: 10.1158/1078-0432.CCR-17-0890. Epub 2017 Aug 29.

47.

Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.

Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, Beier D, Jones DTW, Pietsch T, Schild HH, Hattingen E, Hau P.

AJNR Am J Neuroradiol. 2017 Oct;38(10):1892-1898. doi: 10.3174/ajnr.A5313. Epub 2017 Aug 10.

48.

HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases.

Appay R, Macagno N, Padovani L, Korshunov A, Kool M, André N, Scavarda D, Pietsch T, Figarella-Branger D.

Am J Surg Pathol. 2017 Sep;41(9):1254-1260. doi: 10.1097/PAS.0000000000000866.

PMID:
28704208
49.

A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report.

Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers.

Eur J Cancer. 2017 Aug;81:206-225. doi: 10.1016/j.ejca.2017.04.019. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:.

50.

Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification.

Andreiuolo F, Le Teuff G, Bayar MA, Kilday JP, Pietsch T, von Bueren AO, Witt H, Korshunov A, Modena P, Pfister SM, Pagès M, Castel D, Giangaspero F, Chimelli L, Varlet P, Rutkowski S, Frappaz D, Massimino M, Grundy R, Grill J; SIOP Ependymoma Biology Working Group BIOMECA (BIOlogical Markers for Ependymomas in Children and Adolescents).

PLoS One. 2017 Jun 15;12(6):e0178351. doi: 10.1371/journal.pone.0178351. eCollection 2017.

Supplemental Content

Loading ...
Support Center